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Depression and anxiety are common in people with dementia and
mild cognitive impairment (MCI). Estimates of prevalence of
depressive symptoms in people with dementia range between 10
and 62%,1 with substantially lower rates when employing strict
criteria for major depression.2 People with MCI are also susceptible
to depression, with rates reported as moderate at 36%3 to high at
63%.4 Anxiety symptoms are equally frequent, if not more prevalent,
with rates between 8 and 71%5 for people with dementia and
between 10 and 74%6 for people with MCI. Relatively less is known
about prevalence of anxiety disorders in dementia and MCI, with
rates up to 49% for anxiety-specific disorders7 when using the
Consortium to Establish a Registry for Alzheimer’s Disease
Behavioral Rating Scale for Dementia (CERAD-BRSD) criteria.8
Anxiety and depression have a substantial impact on outcomes
as they decrease the ability to live independently,9,10 increase the
risk of institutionalisation11,12 and result in higher caregiver
burden.13,14 In people with MCI, early symptoms of depression
can often be resistant to antidepressants,15 whereas both
depression and anxiety have been found to predict higher rates
of progression to Alzheimer’s disease.16
Recent recommendations have stressed that the treatment of
anxiety and depressive symptoms should be an essential part of
the treatment of Alzheimer’s disease and other dementias.17
Although pharmacological approaches are commonly used for
anxiety and depression in dementia, these can have side-effects
and remain largely ineffective.18 Further limitations include only a
small number of trials conducted to date with small sample sizes,19
with most studies investigating classes of antidepressants not used
routinely in treating depression in people with dementia in clinical
practice.20,21 Therefore, psychological treatments adapted for use
with people with cognitive impairment may offer an alternative
approach. Other reviews have concluded that psychotherapy reduces
depression in older adults with depressive symptoms22 and that
psychological treatments can increase general psychological well-
being in late-life depressive disorders.23 There are no reviews of
studies, however, evaluating psychological treatments in people with
dementia andMCI. In contrast to previous reviews, the present review
focuses on psychological interventions for people with dementia or
MCI, defined as any psychotherapeutic approach aimed at treating
depression and anxiety, according to the World Health Organization
criteria, such as cognitive–behavioural therapy (CBT), psycho-
dynamic therapy, interpersonal therapy and supportive counselling.24
So, in comparison to previous reviews evaluating interventions
that target anxiety and depression by incorporating some psycho-
logical elements (e.g. reminiscence25), or focusing on environmental
changes26 or exercise,27 the primary objective of this review was to
determine whether psychological interventions reduce depression
and anxiety in people with dementia and MCI. Secondary
objectives were to assess whether: (a) psychological interventions
improve patient quality of life, cognition, activities of daily living
(ADL), and reduce behavioural and psychological symptoms of
dementia other than anxiety and depression compared with usual
care; and (b) whether psychological treatments improve caregiver
quality of life or reduce caregiver burden. This article is based on a
Cochrane Review by the same authors, with full details of the
review published by the Cochrane Library.28
Method
We searched the Cochrane Dementia and Cognitive Improvement
Group’s Specialized Register and major healthcare databases, such
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Background
Anxiety and depression are common in people with
dementia and mild cognitive impairment (MCI), but there is
uncertainty about the effectiveness of both pharmacological
and psychological therapies.
Aims
To evaluate the evidence of effectiveness of psychological
treatments in treating depression and anxiety in people with
dementia and MCI.
Method
We carried out a systematic review and meta-analysis of
randomised controlled trials (RCTs) of psychological
treatment versus usual care in people with dementia and
MCI. Primary outcomes were symptoms of anxiety and
depression. Secondary outcomes were quality of life, ability
to perform daily activities, neuropsychiatric symptoms,
cognition and caregivers’ self-rated depressive symptoms.
Results
We included six RCTs, involving 439 participants with dementia,
which used cognitive–behavioural therapy, interpersonal
therapy, counselling or multimodal interventions including a
specific psychological therapy. We found beneficial effects
for both depression and anxiety. Overall, the quality of the
evidence was moderate for depression and low for anxiety,
due to the methodological limitations of the studies we
identified and the limited number of trials.
Conclusions
The evidence from six RCTs suggests that psychological
treatments are effective in reducing symptoms of depression
and anxiety for people with dementia. There is a need
for high-quality, multicentre trials including standardised,
well-defined interventions.
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as MEDLINE, Embase, CINHAL, PsycINFO, ALIOS and LILACS;
our search also included a number of grey literature sources.
Database searching was completed in January 2013. We searched
for all ‘Treatment MCI’ and ‘Treatment Dementia’ studies with
additional relevant terms. To view a list of all sources searched
for the ALOIS database, see the ALOIS website (www.medicine.
ox.ac.uk/alois/). We searched the identified citations for additional
trials and contacted the corresponding authors of the identified
trials for additional references and unpublished data. We scanned
the reference lists of the identified publications and all review
papers that were related to depression and anxiety in dementia
and MCI.
We included all randomised controlled trials (RCTs) that
included a control group (usual care) or comparison group
receiving no specific psychological intervention. Additional criteria
were that the study provided adequate information about study
design and results, and separate data on participants with dementia
or MCI. Inclusion criteria for participants were older adults
diagnosed with dementia, Alzheimer’s disease or organic brain
syndrome, according to the DSM-IV, ICD-10 or comparable,
and participants with a diagnosis of MCI, in any setting (e.g. home,
community, institution). Any definition of MCI was acceptable as
long as the criteria used were published and included evidence of
objective cognitive impairment but no dementia.29–31
In this review, we considered any psychological therapy
designed to reduce depressive and anxiety symptoms in people
with dementia, which was defined as any intervention that: (a)
was designed to reduce anxiety and depression or improve
adaptive functioning; (b) was based on a psychological theory;
and (c) involved a structured interaction between a facilitator
and a participant, incorporating psychological methods. Eligible
interventions included: (a) CBTs (which include CBT, cognitive
analytic therapy, behavioural therapy or behaviour management
therapy, brief rational insight and problem-solving therapy); (b)
relaxation training therapies (e.g. progressive muscle relaxation);
(c) psychodynamic therapies (including brief psychotherapy and
insight-orientated psychotherapy); (d) interpersonal therapies;
and (e) supportive/counselling therapies. We excluded treatments
identified as medication, exercise, reminiscence therapy, music
therapy, art and drama therapy, befriending or bibliotherapy.
Control conditions included no treatment (usual care) or a
comparison group engaging in non-specific psychosocial activity
(e.g. attention control, controlling for effects of staff attention
or social contact). We did not consider comparisons with other
therapeutic interventions in this review. We included studies that
used combinations of different psychological treatments or
combinations of pharmacological and psychological interventions.
Primary outcomes were depression and anxiety, including
clinician, caregiver and self-ratings. Secondary outcomes were
patient quality of life, cognition, daily activity level (e.g. ADL),
frequency of neuropsychiatric symptoms (e.g. Neuropsychiatric
Inventory, NPI), and caregivers’ quality of life or experience of
caregiver burden.
Two reviewers (V.O., A.Q.) worked independently to identify
RCTs that met the inclusion criteria, and extracted data
independently. They discussed any disagreements with the fourth
(M.O.) and third author (A.S.). We contacted the authors of the
primary trials if there were doubts regarding missing data or the
methodological details of the trial. We employed the approach
recommended by the Cochrane Handbook for Systematic
Reviews of Interventions (Cochrane Collaboration, Oxford, UK;
see http://handbook.cochrane.org/), for assessing risk of bias,
addressing the domains of sequence generation, allocation
concealment, masking, incomplete outcome data, selective
reporting and other issues. We used a fixed-effects model to
represent overall estimate effects. We used standardised mean
differences in some of the analyses as not all studies used the same
outcome scale. We conducted all calculations with RevMan 5.0 for
Windows (Cochrane Collaboration, Oxford, UK; see http://tech.
cochrane.org/revman/download). We assessed heterogeneity
between the included studies with the chi-squared test.32 We
considered P-values 50.10 to be statistically significant. We
quantified heterogeneity by using the I 2 statistic.
Results
We identified a total of 349 references through database searching
(January 2013), with three additional references identified (i.e.
reference lists of identified studies and reviews of the literature).
After removal of duplicates and clearly irrelevant articles, we
retrieved 62 full text records. Of these 62 references, we could
exclude 22 at this stage as not relevant, leaving 40 full text
references to be fully assessed for eligibility. Of these, we
excluded a total of 32 studies as they did not meet the review
criteria, one study is ongoing and one study is awaiting
classification, with further information required to clarify whether
it would meet the inclusion criteria of this review. Thus, we found
six studies to be eligible for inclusion. See Fig. 1 for details of the
search process.
Description of studies
The main study characteristics are shown in online Table DS1. We
were able to pool data for depression from all six studies.33–38
When testing the effects of psychological treatment on anxiety
only two studies contributed data. We pooled data from three
and two studies for self-rated and caregiver-rated quality of life
respectively. We pooled data from two studies to test the effects
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349 records
identified through
database searching
22 records excluded
as not relevant
32 of full-text articles
excluded as they did
not meet review criteria
1 reference classified
as awaiting classification,
and 1 study is ongoing
3 additional records
identified through
other sources
62 records remain to be
screened via full text after
duplicates were removed
62 records screened
via full text
40 full-text articles
assessed for eligibility
6 studies included
in qualitative synthesis
6 studies included
in quantitative synthesis
for meta-analysis 1,
2 studies included for
meta-analysis 2, 3, 6, 7 and 8,
3 studies for meta-analysis
5 and 10, and 4 studies
for meta-analysis 9
6
6
6
6
6
7
7
Fig. 1 Review and meta-analysis flow diagram.
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of psychological treatment on ADL and on the effects on neuro-
psychiatric symptoms. We pooled four studies for analyses on the
effects on cognition. No evidence of heterogeneity was detected
in the pooled studies, using the chi-squared test. The final analysis
included pooled data from three studies on the effects of caregiver
depression. In this analysis heterogeneity was evident.
Primary outcomes
Depression
The first meta-analysis on the effects of psychological treatment
on depression included 439 participants. Results significantly
favoured psychological treatment (6 studies, standardised mean
difference (SMD) 70.22; 95% CI 70.41 to 70.03) in reducing
depressive symptoms for people with dementia (Fig. 2), with little
heterogeneity between studies (I 2 = 21%).
Anxiety
Psychological treatment reduced clinician-rated anxiety measured
with the Rating Anxiety in Dementia scale (Fig. 3) (2 studies, 65
participants, mean difference (MD) 74.57; 95% CI 77.81 to
71.32). However, there was no effect on self-rated anxiety (Fig. 4)
(2 studies, 65 participants, SMD 0.05; 95% CI 70.44 to 0.54) or
caregiver-rated anxiety measured with the NPI-Anxiety (Fig. 5)
(1 study, 26 participants, MD 72.40; 95% CI 74.96 to 0.16).
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Burgener et al 33
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Spector et al 35
Stanley et al 36
Tappen & Williams37
Waldorff et al 38
Total (95% CI)
Heterogeneity: w2 = 6.33, d.f. = 5 (P=0.28); I 2 = 21%
Test for overall effect: Z=2.30 (P=0.02)
Mean
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5.4
10.38
8.2
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5.05
s.d.
2.9
2.6
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19
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216
Mean
4.3
5.5
16.72
7.8
19.13
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s.d.
3.4
3.1
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7.37
5.07
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20
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15
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223
Weight
7.4%
9.3%
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6.8%
62.7%
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IV, fixed, 95% CI
70.31 (71.01, 0.38)
70.03 (70.65, 0.59)
70.95 (71.62, 70.28)
0.08 (70.70, 0.86)
70.46 (71.18, 0.27)
70.15 (70.39, 0.09)
70.22 (70.41, 70.03)
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Fig. 2 Forest plot of psychological treatment versus treatment as usual. Outcome: 1.1 Depression.
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Fig. 3 Forest plot of psychological treatment versus treatment as usual. Outcome: 1.2 Anxiety RAID. RAID, Rating Anxiety in Dementia scale.
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Heterogeneity: w2 = 0.14, d.f. = 1 (P=0.71); I 2 = 0%
Test for overall effect: Z=0.21 (P=0.83)
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7.25
3.9
s.d.
3.338
3.57
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11
32
Mean s.d.
6.78 3.843
4.2 5.2
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18
15
33
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60.4%
39.6%
100.0%
IV, fixed, 95% CI
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70.06 (70.84, 0.71)
0.05 (70.44, 0.54)
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Fig. 4 Forest plot of psychological treatment versus treatment as usual. Outcome: 1.3 Anxiety (self-ratings).
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Fig. 5 Forest plot of psychological treatment versus treatment as usual. Outcome: 1.4 Anxiety NPI-A. NPI-A, Neuropsychiatric
Inventory-Anxiety.
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Secondary outcomes
Quality of life
Psychological treatment had no effect on patient self-rated quality
of life (online Fig. DS1) (3 studies, 334 participants, MD 0.37;
95% CI71.01 to 1.75) or on caregiver-rated patient quality of life
(online Fig. DS2) (2 studies, 313 participants, MD 0.66; 95% CI
70.77 to 2.09).
Activities of daily living
Psychological treatment had no effect on ADL for people with
dementia (online Fig. DS3) (2 studies, 313 participants, SMD
70.13; 95% CI 70.35 to 0.09).
Neuropsychiatric symptoms
Psychological treatment had no effect on neuropsychiatric
symptoms (online Fig. DS4) (2 studies, 311 participants, SMD
0.06; 95% CI 70.16 to 0.28).
Cognition
Psychological treatment had no effect on cognition (online Fig.
DS5) (4 studies, 381 participants, MD 70.80; 95% CI 71.70 to
0.11).
Caregiver depression
Psychological treatment for people with dementia had no effect on
caregivers’ depressive symptoms (online Fig. DS6) (3 studies, 337
participants, SMD 0.07; 95% CI 70.14 to 0.29), with moderate
heterogeneity between studies in this analysis.
Adverse events
None of the studies reported or described any adverse events.
Discussion
The results of six RCTs with a total of 439 participants (216
receiving psychological treatment, 223 in control groups) showed
that psychological treatments reduce depressive symptoms in
people with dementia. Data from two studies showed that
psychological treatments benefit people with dementia by
reducing anxiety symptoms measured with a clinician-rated tool.
These results compare favourably with recent studies, which found
minimal or no benefits of pharmacological interventions in
treating depression in dementia.39 Although both anxiety and
depression were primary outcomes for this review, only two
suitable studies included data for anxiety, and there was no effect
of psychological treatment on secondary outcomes, such as ADL,
quality of life, neuropsychiatric symptoms and cognition, or on
caregiver depression.
The psychological therapies considered in this review stem
from various theoretical perspectives, and in all studies individual
protocols described the therapies in detail. Moreover, all studies
targeted symptoms of anxiety and depression through a structured
psychological approach (therapist and patient communication),
which included directly teaching people with dementia skills to
reduce anxiety and depression. Nevertheless, the trials we have
included in this review evaluated a range of different psychological
interventions and some used a combination of treatments.
The length and duration of intervention also varied in the
studies, leading to differences in intensity and frequency of the
psychological treatment. A limitation of this review, therefore, is
the substantial variation between studies in terms of the nature,
duration and intensity of the psychological therapy evaluated,
which may contribute to difficulties when interpreting the data.
No trials of psychological treatment aimed at people with
MCI met our inclusion criteria. The three studies identified either
did not employ an RCT design, participants had a cognitive
impairment that was not specified according to the established
criteria of MCI or the intervention that was evaluated was
psychologically based but specifically targeted cognitive decline.
None of the studies included reported adverse events.
Quality of the evidence
Risk of bias was unclear for multiple domains in a large
proportion of the studies, with the information provided by the
published reports proving insufficient to determine the risk of bias
associated with key methodological indicators. We classified only
one of the studies as low risk in all domains of the Cochrane
Collaboration’s tool for assessing risk of bias. We classified the
remaining five studies as being at unclear risk of bias in certain
domains, due to limitations such as uncertainties about random
sequence generation, allocation concealment, masking of
participants and personnel, and outcome assessment. There was
also evidence of selective reporting in one trial. Based on the
Grades of Recommendation, Assessment, Development and
Evaluation (GRADE) system, we have classified the quality of
the evidence as ‘moderate’ for depression and ‘low’ for anxiety,
due to the methodological limitations and the limited number
of trials.
Overall completeness and applicability of evidence
The studies we included in the present review only partially
answered the research questions we posed. Few studies provided
data on secondary symptoms of anxiety and we could not perform
any subgroup analyses. Most studies to date have been conducted
in the USA and Europe, limiting generalisability to the rest of the
world. In most studies, information on concurrent psychotropic
treatments was limited. Most participants had mild dementia,
but one trial was conducted with nursing home residents who
had more severe dementia.
The review followed guidelines set out by the Cochrane
Collaboration.40 We used a comprehensive and sensitive strategy
to identify studies; the first (V.O.) and second author (A.Q.)
independently conducted the selection of studies, data extraction
and assessments of risk of bias. The present review presents and
discusses all outcomes described in the protocol that were
available for analysis, regardless of whether or not there was
statistical significance. Finally, it is worth noting that there were
differences in terms of acceptance into treatment protocols (for
example, the requirement of criteria for anxiety in two trials),
which is likely to have resulted in some studies that were overly
inclusive and others that exercised more conservative guidelines.
Results showed that psychological treatments are superior to
usual care in reducing depression and anxiety, although we were
not able to investigate whether they are superior to active controls.
However, in some studies the control condition was enriched
beyond usual care, as opposed to standard care, indicating
that the efficacy of psychological therapies may be potentially
underestimated.
The current review is distinctive in systematically analysing
psychological interventions to reduce anxiety or depression that
are conducted primarily with people with dementia, rather than
focusing on environmental changes or skills building for family
caregivers.41 Previous reviews have concentrated on the effectiveness
of other interventions of a psychosocial nature (including
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cognitive stimulation, cognitive rehabilitation, reminiscence and
activity-based interventions), which are not aimed specifically at
anxiety or depression.42,43 These reviews do suggest that non-
pharmacological interventions can be useful, and potentially
cost-effective, in terms of improving psychological outcomes.42,43
However, for some studies there was a lack of clear psychiatric
diagnosis of depression or anxiety, or a low baseline level of
anxiety and depressive symptoms. These factors limit interpretation
of the results, so it is uncertain how far these findings may be
applicable for people with a specific diagnosis of anxiety or
depression, or with higher baseline levels of depression and
anxiety.
Implications for practice and research
There is moderate quality evidence that psychological treatments
can reduce depressive symptoms in people with dementia, and
limited evidence that they can reduce anxiety. Although the effect
size for depression was small, the beneficial effects for anxiety sug-
gest that psychological approaches may be associated with poten-
tial improvements in both depressive and anxiety symptoms. The
findings of this review compare favourably with limited evidence
base on pharmacological treatment for anxiety and current
evidence of weak support for the use of antidepressants when
treating depression in dementia.39 Considering that there were
no adverse events reported related to the use of psychological
treatments, we can conclude that the observed effects are of
meaningful clinical benefit to people with dementia.
The small number of studies in this review and the variations
in the type and duration of treatment make it difficult to draw
conclusions about the best way to provide psychological treat-
ment. There is a need for well-designed, multicentre RCTs that
adhere to the high standards of methodology and reporting,
following the Consolidated Standards of Reporting Trials
(CONSORT) statement. These trials should focus on standardised
theory-based psychological therapies, rather than multimodal
approaches which combine a variety of approaches. The lack of
follow-up data makes it difficult to use this research to inform
evidence-based policy about how best to deliver psychological
therapy services, and this is compounded by the lack of data about
cost-effectiveness. Future studies should also examine the longer-
term effects of psychological treatment for people with dementia.
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Serotonin syndrome
Rabia Ellahi
Numerous food and drug combinations, also ‘legal highs’, may precipitate serotonin syndrome, yet it appears to be rarely diagnosed.
This may be explained by diagnostic overshadowing when physical symptoms are misattributed to mental illness. Some symptoms
of serotonin syndrome (agitation, tremor and rigidity) overlap with presentations in mental illness. Diagnostic confusion may occur
in patients receiving polypharmacy, those receiving medications with previously unknown serotonergic properties or where
unforeseen drug interactions occur. Acute medical presentations with hyperthermia and clonus should prompt holistic review to
exclude other possible aetiologies. Discontinuation of the suspected agent may avert an array of possible serious outcomes.
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3Study or subgroup
Spector et al 35
Stanley et al 36
Waldorff et al 38
Total (95% CI)
Heterogeneity: w2 = 0.78, d.f. = 2 (P=0.68); I 2 = 0%
Test for overall effect: Z=0.52 (P=0.60)
Experimental
Mean s.d. Total
34.05 5.052 21
36.5 4.28 11
38.2 6.6 129
161
Control
Mean s.d. Total
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Fig. DS1 Forest plot of psychological treatment versus treatment as usual. Outcome: 2.1 Quality of life (self-ratings).
Study or subgroup
Spector et al 35
Waldorff et al 38
Total (95% CI)
Heterogeneity: w2 = 0.92, d.f. = 1 (P=0.34); I 2 = 0%
Test for overall effect: Z=0.91 (P=0.36)
710 75 0 5 10
Favours usual care Favours treatment
Mean
34.25
32.6
s.d.
6.086
6.2
Total
21
130
151
Mean
31.72
32.2
s.d.
6.789
6.7
Total
18
144
162
Weight
12.3%
87.7%
100.0%
IV, fixed, 95% CI
2.53 (71.55, 6.61)
0.40 (71.13, 1.93)
0.66 (70.77, 2.09)
Mean difference
IV, fixed, 95% CI
Experimental Control Mean difference
Fig. DS2 Forest plot of psychological treatment versus treatment as usual. Outcome: 2.2 Quality of life (proxy ratings).
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Fig. DS3 Forest plot of psychological treatment versus treatment as usual. Outcome: 2.3 Activities of daily living.
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Fig. DS4 Forest plot of psychological treatment versus treatment as usual. Outcome: 2.4 Neuropsychiatric symptoms.
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Fig. DS5 Forest plot of psychological treatment versus treatment as usual. Outcome: 2.5 Cognition (Mini Mental State Examination).
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Fig. DS6 Forest plot of psychological treatment versus treatment as usual. Outcome: 3.1 Caregiver depression.
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